Table 1 Patient characteristics at enrolment in Arm A vs. Arm B
Arm A Paclitaxel N = 30 | Arm B Paclitaxel + Sorafenib N = 30 | |
|---|---|---|
Age, mean (SD), years | 59.4 (10.4) | 59.0 (9.6) |
ECOG status, n (%) | ||
0 | 23 (76%) | 19 (61%) |
I | 7 (24%) | 11 (39%) |
Number of metastatic sites | ||
< 2 | 14 (46.7) | 9 (30) |
> = 2 | 16 (53.3) | 21 (70) |
Hormone receptor status, n (%) | ||
ER+ or PR+ | 25 (83.3) | 24 (80.0) |
ER- and PR- | 5 (16.7) | 6 (20.0) |
Pre-treatment with bevacizumab | ||
No | 7 (23.3) | 8 (26.7) |
Yes | 23 (76.7) | 22 (73.3) |
Line of therapy, n (%) | ||
Second-line | 20 (66.6) | 21 (70.0) |
Third-line | 10 (33.3) | 9 (30.0) |
Taxan pretreatment n (%) | ||
No | 23 (76.7) | 20 (66.7) |
Yes | 7 (23.3) | 10 (33.3) |